Angiotensin II treatment in COVID-19 patients: more risk than benefit? A single-center experience

Crit Care. 2020 Jul 9;24(1):409. doi: 10.1186/s13054-020-03143-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Angiotensin II / therapeutic use*
  • COVID-19 / drug therapy
  • Coronavirus Infections / drug therapy
  • Humans
  • Risk Assessment
  • Treatment Outcome

Substances

  • Angiotensin II

Supplementary concepts

  • COVID-19 drug treatment